CStone Pharmaceuticals' lower P/S ratio is due to its perceived limited future growth. Analysts' inferior revenue outlook contributes to its low P/S, making a significant share price rise unlikely soon.
CStone Pharmaceuticals' low P/S ratio is due to its poor revenue outlook. The market anticipates limited growth, paying less for the stock. These conditions form a barrier for the share price.
HBM gets health boost from drug licensing deals December 22, 2023 2142.HK 1.56 (-2.5%) The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion HBM Holdin...
The company's lack of profit over the last year prompts caution despite recent insider purchase showing confidence. Caution urged before investing in CStone Pharmaceuticals, despite insiders seeing potential value.
$CSTONE PHARMA-B (02616.HK)$ Clinical approvals continue to be obtained. That's not good for the market. It becomes a bad day. That means the company will continue to burn cash. After entering shenzhen-Hong Kong stock connect, trading volume is even more depressed. Cornerstones become stepping stones. There was no agency to recommend it. Share prices have given up all this year's gains. This is cstone's darkest hour.
An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data. An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data.
CSTONE PHARMA-B Stock Forum
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...
Clinical approvals continue to be obtained. That's not good for the market. It becomes a bad day. That means the company will continue to burn cash. After entering shenzhen-Hong Kong stock connect, trading volume is even more depressed. Cornerstones become stepping stones. There was no agency to recommend it. Share prices have given up all this year's gains. This is cstone's darkest hour.
Transaction
let go too early!
loading...
No comment yet